Search
Semaglutide Treatment Options
A collection of 186 research studies where Semaglutide is the interventional treatment. These studies are located in the United States. Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
73 - 84 of 186
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo
Active Not Recruiting
This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/10/2025
Locations: Pinnacle Research Group, Anniston, Alabama +15 locations
Conditions: Obesity
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Completed
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on an empty stomach and not eat or drink anything for at least 30 minutes. The study will last for about 3.5-5 years. Participants will have up to 25 clinic visits and 1 phone ca... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/27/2025
Locations: Healthscan Clinical Trials,LLC., Montgomery, Alabama +472 locations
Conditions: Diabetes Mellitus, Type 2
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Active Not Recruiting
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/27/2025
Locations: Pinnacle Research Group, LLC, Anniston, Alabama +25 locations
Conditions: Obesity, Obese, Overweight or Obesity
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
Recruiting
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
02/24/2025
Locations: Childrens Hospital Colorado, Aurora, Colorado
Conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Active Not Recruiting
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Aurora FDRC Inc., Costa Mesa, California +23 locations
Conditions: Obesity
A Study of a Novel Precision Medicine Approach for Obesity
Recruiting
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/21/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida +1 locations
Conditions: Obesity
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
Completed
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.
The study is being conducted to see how well semaglutide, in combination with different doses of NNC0480-0389, work to lower blood sugar levels. Results from this study will be used to select the doses of the two medicines for other studies.
Participants will either get:
Semaglutide (a medicine doctors can already prescribe for treatment of type 2 diabetes) in combi... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/19/2025
Locations: Velocity Clin Res-Chula Vista, Chula Vista, California +88 locations
Conditions: Diabetes Mellitus, Type 2
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Recruiting
This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with excess body weight. This study will test the central hypothesis that semaglutide will improve asthma control and reduce airway inflammation due to direct effects on the respiratory tract in adult asthma associated with obesity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Asthma
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Recruiting
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
Primary Outcomes:
* Residual gastric volume that precludes adequate endoscopic examination
* Residual gastric volume that necessitates premature termination of the endoscopy procedure
* Need for endotracheal intubation due to stomach contents.
* Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hos... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/17/2025
Locations: Cleveland Clinic, Weston, Florida +1 locations
Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Recruiting
Background:
In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
Objective:
To find out how the liver in people with NAFLD responds to feeding, and how this relates to their response to the drug semaglutide.
Eligibility:
People with NAFLD and healthy volunteers ages 18 and older
Design:
Participants will be screened with:
Medical history
Physical exam... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
DIALYSIS-TIR Study
Recruiting
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly.
Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: University of North Carolina, Chapel Hill, North Carolina +4 locations
Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Completed
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/10/2025
Locations: The Yale Stress Center: Yale University, New Haven, Connecticut
Conditions: Obesity
73 - 84 of 186